Madrigal to present multiple resmetirom abstracts at EASL Congress

Madrigal Pharmaceuticals announced ten data presentations at the upcoming European Association for the Study of the Liver, EASL, Congress, taking place from June 5-8, 2024 in Milan, Italy. “The data we will be presenting at EASL further support Rezdiffra as the foundational therapy in NASH and Madrigal as the leading company in the field,” said Bill Sibold, Chief Executive Officer of Madrigal. “We look forward to sharing multiple new data analyses from the MAESTRO Phase 3 program, including the first quality of life data, further analysis of noninvasive test results, and the first look at Rezdiffra in patients with metabolic dysfunction- and alcohol associated liver disease.”